US2521311074 - Common Stock - After market: 106.72 0 (0%)
NASDAQ:DXCM (1/27/2023, 7:03:49 PM)+0.07 (+0.07%)
GICS Sector | Health Care | ||
GICS Industry | Health Care Equipment & Supplies |
Valuation | Growth | ||
Profitability | Health | ||
Dividend |
Earnings (Last) | 10-27 2022-10-27/amc | Earnings (Next) | 02-08 2023-02-08 |
Ins Owners | 0.29% | Inst Owners | 94.15% |
Market Cap | 41.22B | Shares | 386.26M |
PE | 152.46 | Fwd PE | 96.99 |
Dividend Yield | N/A | Analysts | 86.4 |
IPO | 04-14 2005-04-14 |
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find more growth stocks the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
DexCom, Inc. is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. The company is headquartered in San Diego, California and currently employs 6,300 full-time employees. The company went IPO on 2005-04-14. The firm is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for use by people with diabetes and by healthcare providers. Its Dexcom G6 is a CGM system that can be used as part of an integrated system with other compatible medical devices and electronic interfaces, which may include automated insulin dosing systems, insulin pumps, blood glucose meters or other electronic devices used for diabetes management. Its Dexcom Share remote monitoring system, offered for use with its Dexcom system, uses an application on the patient's mobile device to wirelessly transmit glucose information to the cloud and then to applications on the mobile devices of up to five designated recipients. Its Dexcom Real-Time API enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices. Its other products include Dexcom ONE and Dexcom G7.
DEXCOM INC
6340 Sequence Dr
San Diego CALIFORNIA 92121
P: 18582000200.0
CEO: Kevin R. Sayer
Employees: 6300
Website: https://www.dexcom.com/
At least four Wall Street banks recently raised their price targets for the healthcare giant.
In diabetes device market, Wolfe has granted an Outperform rating for DexCom (DXCM), and Peer Perform ratings for Tandem Diabetes (TNDM) and Insulet (PODD). Read the full story here.
Jefferies has released its inaugural global stock picks list, with the bank favoring names such as Estee Lauder, Sony, Alibaba, Prudential, ASML, Nvidia and Caterpillar. Read more here.
Plus, Dexcom CEO Kevin Sayer shares some insight on continuous glucose monitors.
Don't overlook these growth plays.
Here you can normally see the latest stock twits on DXCM, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: